Merck, Lundbeck end development of Phase III insomnia drug

Share this article:
Merck and Lundbeck have scrapped their joint-development program for insomnia treatment gaboxadol. In a joint-statement, the companies said data from recently completed clinical studies suggests the overall clinical profile for gaboxadol “does not support further development.” As a result Merck and Lundbeck said they will not file a new drug application (NDA) with the FDA or other regulatory agencies. Ongoing clinical studies are to be terminated. In October, Lundbeck and Merck extended the target date to submit a NDA for gaboxadol with the FDA to mid-2007 from the first quarter of 2007, because of slower than anticipated enrollment in ongoing Phase III trials. The companies agreed in 2004 to collaborate on the development and commercialization of gaboxadol in the US Lundbeck would have received a milestone payment of $75 million from Merck if it moved forward with an application for US registration of gaboxadol.
Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union